Related Experiment Video

Updated: May 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies

Giulia M Stella1, Maurizio Luisetti, Simona Inghilleri

  • 1Department of Hematological, Pneumological and Cardiovascular Sciences, Section of Pneumology, University and Fondazione IRCCS Policlinico, San Matteo, 27100 Pavia, Italy. g.stella@smatteo.pv.it

Respiratory Medicine
|November 23, 2011
PubMed

Insights

Targeted cancer therapies are most effective when matched to a patient's genetic profile. This review focuses on genetic mutations in lung cancer, particularly those affecting the EGFR pathway, as key indicators for successful targeted drug response.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • Cancer is fundamentally a genetic disease, driving research into targeted therapies.
  • Understanding gene mutations is crucial for predicting patient response to cancer drugs.
  • Targeted treatments, like tyrosine kinase receptor inhibitors, show success in specific tumor subsets dependent on particular genetic alterations.

Purpose of the Study:

  • To review the current state of molecularly-tailored pharmacological approaches for lung cancer.
  • To highlight the significance of genetic lesions in the EGFR pathway as predictive markers for targeted therapy response.

Main Methods:

  • Literature review of molecularly-tailored pharmacological approaches in lung cancer.
  • Analysis of genetic alterations, focusing on the EGFR pathway.
  • Examination of the role of these genetic lesions as markers for targeted drug efficacy.

Main Results:

  • Genetic profiling of tumors is essential for personalized cancer treatment.
  • Specific mutations activating EGFR pathway transducers are strong indicators of targeted drug response in lung cancer.
  • Targeted therapies are most effective in tumors with a genetic addiction to specific signaling pathways.

Conclusions:

  • Molecular-based diagnosis and patient selection are critical for optimizing targeted lung cancer therapies.
  • EGFR pathway genetic lesions serve as vital biomarkers for guiding treatment decisions.
  • Personalized medicine approaches, informed by genetic data, represent the future of lung cancer treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...